Page last updated: 2024-11-04

temozolomide and Optic Nerve Diseases

temozolomide has been researched along with Optic Nerve Diseases in 1 studies

Optic Nerve Diseases: Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.

Research Excerpts

ExcerptRelevanceReference
"The case of a 63 year old woman with glioblastoma multiforme and concomitant radiochemotherapy with temozolomide is described."7.76Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report. ( Bartels, C; Brueggemann, I; Elolf, E; Gademann, G; Galazky, I; Prox-Vagedes, V; Schreiber, S, 2010)
"The case of a 63 year old woman with glioblastoma multiforme and concomitant radiochemotherapy with temozolomide is described."3.76Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report. ( Bartels, C; Brueggemann, I; Elolf, E; Gademann, G; Galazky, I; Prox-Vagedes, V; Schreiber, S, 2010)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schreiber, S1
Prox-Vagedes, V1
Elolf, E1
Brueggemann, I1
Gademann, G1
Galazky, I1
Bartels, C1

Other Studies

1 other study available for temozolomide and Optic Nerve Diseases

ArticleYear
Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report.
    BMC cancer, 2010, Oct-01, Volume: 10

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy; Female; Glioblastoma; Humans; Hypericu

2010